https://www.selleckchem.com/pr....oducts/ly2157299.htm
immune checkpoint inhibitors(ICIs) have shown contradictory results in patients with advanced gastro-oesophageal junction/gastric cancer(GOJ/GC). to identify specific patient subgroups that would derive survival benefit from ICIs. a subgroup meta-analysis of randomised clinical trials(RCTs) was carried out. four phase-III-RCTs were identified with data on the following variables primary location(Gastric vs GOJ); age(≤ 65 vs 65); gender(male vs female); ECOG PS(0 vs 1); ethnicity (Asian vs non-Asian), histology(intestinal vs diffus
Like
Comment
Share
